PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

AUC-Guided Vancomycin in Severe Renal Impairment: Underpowered but Directionally Favorable

vancomycinglycopeptideAUC-guided dosingtrough-guided dosingmodel-informed precision dosingBayesian estimationacute kidney injurysevere renal impairmenttherapeutic drug monitoringretrospective cohortpharmacokinetics Pharmacokinetics / TDM

Background Information

Can AUC-guided vancomycin dosing reduce kidney risk in renal impairment?

Vancomycin dosing using area under the curve (AUC) guidance may reduce acute kidney injury (AKI) risk in patients with impaired renal function. AKI occurred in 22.7% of trough-guided vs. 10.0% of AUC-guided patients, with no significant difference (p = 0.29). No significant difference was found between dosing methods, but AUC-based dosing might be safer for severely impaired renal function. AUC-guided vancomycin dosing may lessen AKI risk in severe renal impairment.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Fujita K, Yamamoto K, Itohara K, Ogihara T, Sakaue T, Uda A, Morioka A, Yamashita K, Omura T, Yano I

Citation: Fujita K, Yamamoto K, Itohara K, et al. Incidence of Acute Kidney Injury in the Model-Based AUC-Guided Dosing of Vancomycin Compared with Conventional Trough-Guided Dosing in Patients with Severely Impaired Renal Function. Biological & pharmaceutical bulletin. 2026;49(10):1709-1717. doi:10.1248/bpb.b26-00361

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.